Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Khaled Maman
Institution:
BioMarin (United Kingdom)
Observed institutions:
BioMarin (United Kingdom),
Creativ-Ceutical (France),
Alimentiv Inc. (Canada)
OpenAlex ID:
A5113670535
Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison
2013
·
Khaled Maman
, Samuel Aballea
, et al.
·
European Urology
·
271
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis
2018
·
Con Kelleher
, Zalmai Hakimi
, et al.
·
European Urology
·
247
PDF
The value of childhood combination vaccines: From beliefs to evidence
2015
·
Khaled Maman
, York Zöllner
, et al.
·
Human Vaccines & Immunotherapeutics
·
170
PDF
Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database
2011
·
Dieter Kunz
, Sébastien Bineau
, et al.
·
Expert Opinion on Pharmacotherapy
·
42
Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom
2015
·
Jameel Nazir
, Khaled Maman
, et al.
·
Value in Health
·
37
PDF
The 6-month persistence on SSRIs and associated economic burden
2010
·
Larry Ereshefsky
, Delphine Saragoussi
, et al.
·
Journal of Medical Economics
·
35
PDF
Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder
2013
·
Katia Desroziers
, Samuel Aballéa
, et al.
·
Health and Quality of Life Outcomes
·
32
PDF
Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
2014
·
Samuel Aballéa
, Khaled Maman
, et al.
·
Clinical Drug Investigation
·
31
PDF
Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis
2010
·
Clément François
, Nicolas Despiégel
, et al.
·
Journal of Medical Economics
·
26
PDF
Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings
2016
·
Semukaya Sendyona
, Isaac Odeyemi
, et al.
·
Journal of Market Access & Health Policy
·
24
PDF
Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta‐analysis
2017
·
Jameel Nazir
, Con Kelleher
, et al.
·
Neurourology and Urodynamics
·
23
PDF
Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
2011
·
Rive
, Bart Hoogveldt
, et al.
·
Neuropsychiatric Disease and Treatment
·
12
PDF
Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden
2010
·
Göran Nordström
, Nicolas Despiegel
, et al.
·
Journal of Medical Economics
·
11
PDF
Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
2018
·
Zalmai Hakimi
, Con Kelleher
, et al.
·
Journal of Market Access & Health Policy
·
8
EE667 Socioeconomic Burden Among Children and Adults With Achondroplasia in Europe and Latin America
2025
·
Yichen Zhang
, Anne Dee
, et al.
·
Value in Health
Show more works
View as search
Works count:
15
Citation count:
968
H-index:
12
I10-index:
13
Year
Topic
Type